Magnus Tägil

Moroxite AB is a medtech company based in Lund, Sweden, with subsidiaries in Sweden. Moroxite is developing a portfolio of breakthrough therapies in targeted drug delivery, using innovative nano and micro technology-based platforms. The Swedish company's focus areas include bone regeneration, tumor, and bone infection. The private company has developed a platform for prolonged release of apatite binding drugs, using a carrier containing nano and micro particles. Recently, Moroxite spun-off its bone infection and fracture fixation businesses into independent companies, Moroxite I AB and Moroxite F AB, respectively. Moroxite F AB has raised capital of 10 MSEK in a private placement from two investors, Fåhraeus Startup & Growth and Almi Invest. The company was founded in 2020 by Lars Ã…ke Alvar Lidgren, Magnus Tägil, and Deepak Raina.

Moroxite AB is a medtech company based in Lund, Sweden, with subsidiaries in Sweden. Moroxite is developing a portfolio of breakthrough therapies in targeted drug delivery, using innovative nano and micro technology-based platforms. The Swedish company's focus areas include bone regeneration, tumor, and bone infection. The private company has developed a platform for prolonged release of apatite binding drugs, using a carrier containing nano and micro particles. Recently, Moroxite spun-off its bone infection and fracture fixation businesses into independent companies, Moroxite I AB and Moroxite F AB, respectively. Moroxite F AB has raised capital of 10 MSEK in a private placement from two investors, Fåhraeus Startup & Growth and Almi Invest. The company was founded in 2020 by Lars Ã…ke Alvar Lidgren, Magnus Tägil, and Deepak Raina.